Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07120607) titled 'Allogeneic CD7 CAR ?d T Cells Therapy Recurrent/Refractory Leukemia' on Aug. 5.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Anhui Provincial Hospital
Condition:
Leukemia
Intervention:
Biological: CD7 CAR-?dT cell(QH106)
Drug: Fludarabine (FLU)
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: August 18, 2025
Target Sample Size: 9
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07120607
Disclaimer: Curated by HT Syndication....